Hill Stephen J. sold $2K of LYEL
Hill Stephen J. (Chief Operating Officer) sold 89 shares of Lyell Immunopharma, Inc. (LYEL) at $18.92 on 2026-05-11.
How this was made
The 30-second read
Why it matters
The newest information is the officer’s reported open-market sale details (date, shares, price, post-transaction holdings).
Market read
Traders may monitor insider activity as a sentiment input, but this specific disclosure lacks a fundamental catalyst.
What to watch
The filing does not state the insider’s broader trading schedule or whether other grants/sales occurred around the same period; also, the sale size is small relative to typical institutional flows.
Background
The article is an SEC Form 4 insider transaction disclosure for Lyell Immunopharma, Inc.
Ticker impact
Lyell Immunopharma COO Stephen J. Hill filed an open-market sale of 89 shares at $18.92 on 2026-05-11 via Form 4.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
This is a small, disclosed open-market sale by an officer with no 10b5-1 plan indicated; size is modest and there is no accompanying operational/regulatory catalyst in the filing.
Market effects
No clear sector read-through; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Insider sales can be driven by diversification/tax needs and may not reflect bearish views, especially when not tied to a specific negative event.
Key entities
- issuerLyell Immunopharma, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderStephen J. Hill
Chief Operating Officer who sold 89 shares in an open-market transaction.